Drug

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance
AbbVieNYSE: ABBV

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie Inc. (NYSE: ABBV) announced that China's National Medical Products Administration (NMPA) has approved RINVOQ (upadacitinib extended‑release tablets, 15 mg and 30 mg, once daily) for the treatment of adults…

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Qilu Pharmaceutical's QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Qilu Pharmaceutical’s QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion
NMPA

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion

China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity
DiabetesHot targets

China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity

Genmab Discontinues Acasunlimab to Focus on Late‑Stage Portfolio
GenmabMulti-specific antibodies

Genmab Discontinues Acasunlimab to Focus on Late‑Stage Portfolio

Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy
AmgenBeiGene

Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy

Show More